Anakinra is relatively safe, modestly effective in rheumatoid arthritis
Anakinra is a relatively safe and modestly effective biologic therapy for rheumatoid arthritis, according to a systematic review published online on January 21 in the Cochrane Database of Systematic Reviews.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that virtually the same percentage of surveyed rheumatologists selected Amgen/Pfizer/Takeda's Enbrel and Abbott/Eisai's Humira as the most efficacious agent for the treatment of rheumatoid arthritis.